Since 2016, insurance companies in the European Union have to comply with Solvency II regulation. This Directive imposes equity solvency capital requirements. This means that insurance companies have to hold a capital buffer to survive adverse shocks in financial markets. Most European pension funds are still subject to local regulation, but these local frameworks tend to resemble Solvency II.
Under Solvency II the standard solvency capital requirement (SCR) for a diversified equity portfolio is 39% for stocks listed in developed markets and 49% for those listed in emerging markets. This SCR is adjusted up or down with a maximum of 10 percentage points, depending on the equity market’s past three-year performance. The equity SCR is intended as a means to keep the probability of bankruptcy over the next twelve months below 0.5%.
Solvency II has a different equity solvency capital requirement for developed market stocks (39%) percent) and emerging market stocks (49%). This makes sense, as there is a difference in financial economic risk between the two types of markets. However, differences in financial economic risk within developed or emerging markets are not taken into account. This has two unintended, potentially detrimental consequences:
We will explain why. First of all, within developed or within emerging equity markets, the risk of each equity portfolio is assumed to be the same. If you assume that more risk should lead to more return, this regulation creates an incentive to buy more risky stocks. This can be seen in Figure 1, where we depict a low-risk (blue) and a high-risk (red) portfolio. Solvency II assumes the risk for each of these two portfolios to be the same as the market’s, as indicated by the blue and red circles. As a result, the Solvency II investor does not face a risk-return trade-off, but can choose the highest return regardless of financial economic risk. Instead of promoting prudency, Solvency II therefore encourages risk-seeking behavior.
This is linked to the second unintended consequence of Solvency II. If large enough pools of capital are exposed to Solvency II-type regulation, the price of high-risk stocks is driven up more than warranted by their economic risk, while the price of low-risk stocks is pushed down more than justified by their economic risk. This leads to lower future returns for high-risk stocks, and higher future returns for low-risk stocks. Investors only have an incentive to buy the low-risk stocks when their price has decreased so much that the relation between risk and return has become flat or inverse. Such a distortion between risk and return is indeed observed in practice, and is commonly referred to as the low-risk anomaly. Oversimplified regulation such as the crude Solvency II SCR framework may help create and sustain this anomaly.
We urge European regulators for institutional investors to improve Solvency II by aligning it with more sophisticated European regulation that is already in place for private investors in mutual funds. This would reduce the potential harmful unintended consequences from existing solvency regulation.
Specifically, we propose to multiply the standard solvency charge of 39% with the ratio of the company’s equity portfolio volatility to the broad equity market’s volatility. This is a way to capture a portfolio’s relative risk. The ratio will be above one for more risky portfolios and below one for less risky portfolios, meaning that high-risk stock portfolios require more solvency capital than the market, and low-risk stock portfolios less. In our proposal the distinction between developed (SCR of 39%) and emerging (SCR of 49%) stocks has disappeared. This is because our formula already accounts for this difference.
For the broad equity market we propose to use the MSCI World Index. For volatility, we propose to take the five-year volatility and review this on a quarterly basis. If the company’s equity strategy does not have a representative five-year history, we propose backfilling the equity return history with a representative alternative proxy return series, such as an index that follows a similar investment strategy.
Our proposed approach encompasses the existing distinction between emerging and developed markets, and also takes into account many other potential sources of risk. It is a straightforward and cost-efficient way for asset owners to assess risk, which is already used in regulation for European retail investors. It gives better incentives to institutional investors, contributes to market efficiency and is difficult to manipulate. In short, it reduces potentially harmful, unintended consequences of existing regulation for institutional investors.
This article is an excerpt from the paper “Equity Solvency Capital Requirements: What Institutional Regulation Can Learn from Private Investor Regulation”, which has been accepted for publication in Geneva Papers on Risk and Insurance: Issues and Practice. The working paper can be downloaded here.
The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients.
The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA).
Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile.
Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports.